Results 71 to 80 of about 6,571 (189)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability

, 2013
CY Pan,1 XL Wang21Chinese PLA General Hospital, Beijing, People's Republic of China; 2Medical Affairs Department, Beijing Novartis Pharma Co, Ltd, Beijing, People's Republic of ChinaAbstract: Vildagliptin is a selective and potent dipeptidyl ...
Wang XL, Pan CY
core  

Bullous Pemphigoid Induced by Vildagliptin

, 2015
Bullous pemphigoid (BP) is an uncommon chronic, autoimmune, and subepidermal disease. Tense blisters occur on normal or erythematous skin. It can be induced by medications.
Taskiran, BENGÜR, CANSU, GÜVEN BARIŞ, Cansu, Güven Barış, SOLAK ŞİŞMAN, CANAN, Bahattin Erdoğan, Bengür Taşkıran, Güven Barış Cansu, Sisman, Canan Solak, Erdogan, Bahattin, Canan Solak Şişman   +9 more
core   +1 more source

Vildagliptin uygulamasının pankreas adacık hücreleri üzerine etkisi

, 2011
Bu çalışmanın amacı, sıçanlara oral olarak uygulanan vildagliptinin adacık hücreleri üzerine etkilerini araştırmaktır. Sıçanlara 4 gün vildagliptin 100 mg/kg/gün verildikten sonra adacık hücreleri izole edildi.
GÜLBAHAR BÖYÜK
core   +1 more source

Drug evaluation: Vildagliptin-metformin single-tablet combination

, 2009
The single-tablet combination of vildagliptin and metformin addresses key defects of type 2 diabetes for improved glycemic control. By inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, vildagliptin raises the levels of the active incretin hormones ...
Piya, Milan K, Piya, Milan, Piya, Milan K. (R19111), Barnett, Anthony, Barnett, Anthony H., Tahrani, Abd A., Tahrani, Abd; id_orcid, Barnett, Anthony H, Tahrani, Abd A   +8 more
core   +1 more source

Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-κB Pathway

Frontiers in Pharmacology, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2 diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on cardiovascular system.
Yuqin Ji, Yingbin Ge, Xinyu Xu, Sen Ye, Yuansheng Fan, Jing Zhang, Lianlian Mei, Xiaofeng Zhang, Lianghong Ying, Tao Yang, Chunjian Li   +10 more
doaj   +1 more source

Comparative effect of vildagliptin and teneligliptin on HbA1c, glycemic efficacy and insulin sensitivity [PDF]

, 2017
Background: Vildagliptin, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the availability of endogenous incretin hormones, glucagon-like peptide (GLP-1), and glucose-dependent insulinotropic polypeptide, thereby improving ...
Tushar B. Chudiwal, Chudiwal, Tushar B.
core   +1 more source

Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring

, 2013
AimTo assess whether there is a difference in the effects of vildagliptin and glimepiride on glucose fluctuation in patients with type 2 diabetes mellitus (T2DM) using continuous glucose monitoring (CGM).MethodsThis was an open-label, randomized cross ...
Neelakantham, S, Kulmatycki, K, He, YL, Mattapalli, D, Foteinos, G, Forst, T, Taylor, A   +6 more
core  

Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review

International Journal of Diabetes and Technology
Type 2 diabetes mellitus (T2DM) is a complex disease with multiple pathophysiological defects and generally requires a combination of antidiabetic agents to achieve glycemic targets. In this context, a fixed-dose combination (FDC) of dipeptidyl peptidase-
Subhajyoti Ghosh, Mainak Mukhopadhyay, Mayur Agrawal, Mohammad Shahid, Mahak Lamba, Sudeep Jain, Ashish Prasad, Amit Gupta, Rohan Kesarkar, Sona Warrier, Abhijeet Pednekar   +10 more
doaj   +1 more source

Glycated Albumin‐Guided Therapy: Biomarker Utility or Earlier Treatment Intensification?

Journal of Diabetes, Volume 18, Issue 10, October 2026.
Muhammet Fatih Şahin
wiley   +1 more source

A case of bullous pemphigoid nduced by vildagliptin

, 2017
Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature.
Tas-Aygar, Gamze, Keseroglu, Havva Ozge, GÖKÖZ, ÖZAY, Gonul, Muzeyyen, Ersoy-Evans, Sibel   +4 more
core   +1 more source